Proniras

Seattle, United States

Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.

$4.7M raised

Feb 2024

Series B

Top Investors

ARCH Venture PartnersAccelerator Life Science PartnersWRF CapitalWatson Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Proniras raised?

Proniras has raised $4.7M in total funding. The most recent round was Series B. The last funding was announced in February 2024.

Who are Proniras's investors?

Proniras's investors include ARCH Venture Partners, Accelerator Life Science Partners, WRF Capital, Watson Fund.

Where is Proniras headquartered?

Proniras is headquartered in Seattle, United States.

What does Proniras do?

Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.

What stage is Proniras at?

Proniras is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 1, 2024.

MLA

"Proniras — Funding & Investors." VCBacked, February 1, 2024, https://www.vcbacked.co/company/proniras. Accessed June 4, 2026.

APA

VCBacked. (2024). Proniras — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/proniras

Wikipedia (cite web)

{{cite web |title=Proniras — Funding & Investors |url=https://www.vcbacked.co/company/proniras |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 1, 2024.